Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment.
Strontium ranelate is a new treatment for osteoporosis that results in large increases in BMD, much of which is an artefact caused by high bone strontium content. We used clinical trial data and a model of long-term strontium kinetics to estimate the effect of past strontium treatment on future BMD measurements.


BACKGROUND
The oral administration of strontium ranelate causes a clinically significant overestimation of BMD because of the high attenuation of X-rays by strontium atoms in bone. As more patients are treated with strontium ranelate, questions will arise about the correct interpretation of their future BMD measurements. We performed a theoretical study to calculate the long-term effect of strontium treatment on BMD and establish the duration of past treatment for which the remaining bone strontium content (BSC) has a negligible effect on BMD.


METHODS
The BMD changes measured at the spine and hip during strontium ranelate treatment were interpolated from clinical trial data. The long-term retention of strontium in bone was estimated using the International Commission on Radiological Protection (ICRP) strontium retention function modified for use in postmenopausal women. Estimates of the strontium BMD artefact after treatment has stopped were performed on the assumption that the BSC effect accounts for 75% of the total measured BMD change at 3 years.


RESULTS
If 75% of the BMD changes are explained by BSC, in the average patient, 3-year treatment leads to a spine BMD artefact of 11.2%, decreasing to 3.8% 10 years after stopping treatment. The BMD artefacts at the total hip and femoral neck sites are smaller by factors of 0.65 and 0.53, respectively. If pre- and post-therapy BMD measurements are available, these predictions can be tailored to the individual patient. On average, 6-month treatment is required for the spine BMD artefact to exceed 3%, the figure adopted as the maximum BMD change caused by bone strontium that has a negligible effect on scan interpretation. Ten years after stopping treatment, 28 months of treatment are required for the residual BMD artefact to still exceed the 3% threshold.


CONCLUSIONS
Strontium ranelate treatment lasting for >6 months can affect BMD measurements for many years afterward.
Blake
Glen M
GM
King's College London School of Medicine, London, United Kingdom. glen.bake@kcl.ac.uk
Fogelman
Ignac
I
D015519:Bone Density / Q000187:drug effects*; D005260:Female; D005272:Femur Neck / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000187:drug effects; D005500:Follow-Up Studies; D006615:Hip / Q000033:anatomy & histology / Q000000981:diagnostic imaging; D006801:Humans; D008962:Models, Theoretical; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy; D017698:Postmenopause; D013131:Spine / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000187:drug effects; D013876:Thiophenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D028761:Withholding Treatment
D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate